Voxvoganan

Voxvoganan
Clinical data
Other names	Lytixar
Identifiers
	IUPAC name (2S)-2-amino-5-(diaminomethylideneamino)-N-{(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(2-phenylethylamino)pentan-2-yl]amino]-1-oxo-3-[2,5,7-tri-(tert-butyl)-1H-indol-3-yl]propan-2-yl}pentanamide;
CAS Number	1166254-80-3;
PubChem CID	25242323;
DrugBank	DB12711;
ChemSpider	26611002;
UNII	HO813QDF65;
ChEBI	CHEBI:77752;
ChEMBL	ChEMBL1817968;
CompTox Dashboard (EPA)	DTXSID20151467 ;
Chemical and physical data
Formula	C43H69N11O3
Molar mass	788.099 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)NC(=C2C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC3=CC=CC=C3)NC(=O)[C@H](CCCN=C(N)N)N)C(C)(C)C;
	InChI InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1; Key:ZVOYWSKEBVVLGW-ZDCRTTOTSA-N;

Voxvoganan (LTX-109, Lytixar) is an experimental antibiotic medication for topical use. It is a synthetic peptide which is in clinical trials against skin infections caused by drug-resistant strains of Staphylococcus aureus.^[1]^[2]^[3]^[4]^[5]^[6]

References

↑ Isaksson J, Brandsdal BO, Engqvist M, Flaten GE, Svendsen JS, Stensen W (August 2011). "A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption". Journal of Medicinal Chemistry. 54 (16): 5786–5795. doi:10.1021/jm200450h. PMID 21732630.
↑ Saravolatz LD, Pawlak J, Johnson L, Bonilla H, Saravolatz LD, Fakih MG, et al. (August 2012). "In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus". Antimicrobial Agents and Chemotherapy. 56 (8): 4478–4482. doi:10.1128/AAC.00194-12. PMC 3421571. PMID 22585222.
↑ Nilsson AC, Janson H, Wold H, Fugelli A, Andersson K, Håkangård C, et al. (January 2015). "LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus". Antimicrobial Agents and Chemotherapy. 59 (1): 145–151. doi:10.1128/AAC.03513-14. PMC 4291342. PMID 25331699.
↑ Scott RW, Tew GN (2017). "Mimics of Host Defense Proteins; Strategies for Translation to Therapeutic Applications". Current Topics in Medicinal Chemistry. 17 (5): 576–589. doi:10.2174/1568026616666160713130452. PMID 27411325.
↑ Sakr A, Brégeon F, Rolain JM, Blin O (May 2019). "Staphylococcus aureus nasal decolonization strategies: a review". Expert Review of Anti-Infective Therapy. 17 (5): 327–340. doi:10.1080/14787210.2019.1604220. PMID 31012332.
↑ Heimann D, Kohnhäuser D, Kohnhäuser AJ, Brönstrup M (January 2025). "Antibacterials with Novel Chemical Scaffolds in Clinical Development". Drugs. 85 (3): 293–323. doi:10.1007/s40265-024-02137-x. PMC 11891108. PMID 39847315.

This medical article is a stub. You can help Wikipedia by adding missing information.

[1] Isaksson J, Brandsdal BO, Engqvist M, Flaten GE, Svendsen JS, Stensen W (August 2011). "A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption". Journal of Medicinal Chemistry. 54 (16): 5786–5795. doi:10.1021/jm200450h. PMID 21732630.

[2] Saravolatz LD, Pawlak J, Johnson L, Bonilla H, Saravolatz LD, Fakih MG, et al. (August 2012). "In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus". Antimicrobial Agents and Chemotherapy. 56 (8): 4478–4482. doi:10.1128/AAC.00194-12. PMC 3421571. PMID 22585222.

[3] Nilsson AC, Janson H, Wold H, Fugelli A, Andersson K, Håkangård C, et al. (January 2015). "LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus". Antimicrobial Agents and Chemotherapy. 59 (1): 145–151. doi:10.1128/AAC.03513-14. PMC 4291342. PMID 25331699.

[4] Scott RW, Tew GN (2017). "Mimics of Host Defense Proteins; Strategies for Translation to Therapeutic Applications". Current Topics in Medicinal Chemistry. 17 (5): 576–589. doi:10.2174/1568026616666160713130452. PMID 27411325.

[5] Sakr A, Brégeon F, Rolain JM, Blin O (May 2019). "Staphylococcus aureus nasal decolonization strategies: a review". Expert Review of Anti-Infective Therapy. 17 (5): 327–340. doi:10.1080/14787210.2019.1604220. PMID 31012332.

[6] Heimann D, Kohnhäuser D, Kohnhäuser AJ, Brönstrup M (January 2025). "Antibacterials with Novel Chemical Scaffolds in Clinical Development". Drugs. 85 (3): 293–323. doi:10.1007/s40265-024-02137-x. PMC 11891108. PMID 39847315.

[1]

[2]

[3]

[4]

[5]

[6]